




Transforming healthcare for people with severe mental illness through predictive, data-driven care

CareLoop is a remote monitoring and relapse prevention platform that shifts psychosis care from crisis response to prevention - enabling better outcomes while reducing system costs.



50%

reduction in relapse events

33%

reduction in hospital admission costs

14%

reduction in clinical administration time

≥75%

annual patient adherence

5

randomised controlled trials validate the approach

The challenge

Psychosis affects one in 100 people, typically emerging in adolescence and young adulthood and remains a life-long condition for most, with only 20% achieving full recovery. About 80% of individuals with psychosis will relapse, with a one in four chance every year of experiencing a crisis event. Early warning signs appear three to 10 days before relapse, yet many people go up to 12 weeks between appointments. This creates a worrying gap that leads to preventable emergency admissions, increased risk of disability and significant trauma and disruption for those affected.


Less cost, more care

Despite affecting just 1% of us, psychosis accounts for 30% of NHS mental health spend and 75% of mental health inpatient beds. The lifetime cost of treating someone with psychosis is about six times the cost of treating someone with heart disease. CareLoop halves the chances of relapse in psychosis and keeps people with severe mental illness safely connected to their support teams, so their lives stay on track.

Stigma stifles innovation

The discrepancy between the burden of psychosis and innovation for the condition is huge - treatments remain largely unchanged since the 1950s. It is a highly stigmatised condition, which disproportionately affects those from marginalised communities. CareLoop is here to change this, empowering people to live full lives, extending quality care to underserved and remote communities and helping them manage their condition in the community.

How it works



10-year plan pillar

TREATMENT > PREVENTION

Reducing the relapse burden

Co-designed with patients, clinicians, and researchers, people with psychosis find CareLoop easy to use and stick to, with 75% adherence.

People using CareLoop spend a few minutes each day to gain insights into their own condition, and tell us it helps them to feel empowered, less fearful, and to stay safe.

Those using CareLoop are half as likely to relapse and, if they do, are twice as likely to be treated in community settings where they have their normal support network.

10-year plan pillar

HOSPITAL > COMMUNITY

Impact on emergency admissions

CareLoop has shown 33% cost savings in hospital admissions through proactive intervention, a 14% time saving for clinical staff. Working in partnership with Health Innovation South West (HIN SW), CareLoop Health was awarded £488k by Small Business Research Initiative (SBRI) Healthcare to give patients in South West England access to its platform over the course of a year to test and measure relapse prevention, hospital admissions, and NHS cost savings, as well as uptake, adherence and improvements to self-management in the community.

Cornwall Partnership NHS Foundation Trust, Devon Partnership NHS Trust and Livewell Southwest are the first NHS trusts in the country to trial CareLoop Health's digital platform to prevent psychosis relapse across a region.

10-year plan pillar

ANALOGUE > DIGITAL

Integrating into the NHS

CareLoop Health is partnering with EPR providers, including the Access Group, allowing us to integrate with NHS electronic health records. We are currently integrating into RiO EPR, making it easier for Mental Health Trusts across the country to implement CareLoop as part of an integrated care pathway for people living with severe mental illness.

Supported by Health Innovation Yorkshire & Humber, we are also carrying out real-world evaluation to measure system-wide savings to the NHS.

Recommended on the NICE Early Value Assessment, Careloop is DTAC-approved, ISO 13485 certified, and registered with the MHRA as a Class I medical device, ensuring compliance with the highest standards of clinical effectiveness, data security, and regulatory requirements for digital health technologies in the NHS.



"You felt as if you were improving your condition by paying attention to it. It made you become engaged,"
a CareLoop user

Speak to us today

www.careloop.health | contact@careloop.health

